Clinical Trials

May 31, 2018

TOMORROW: A multicenter, open-label, randomized, event-driven study to assess efficacy, safety and pharmacokinetics of macitentan versus standard of care in children with pulmonary arterial hypertension

• Study Sponsor: Actelion
• Institution: Actelion, a Janssen Pharmaceutical Company of Johnson and Johnson
• Start Date: Tuesday, November 28, 2017
• End Date: Thursday, July 14, 2022
• Design: Background treatment allowed
• Age range (years): From 2 to 17
• Type of PH
  • IPAH
  • Heritable – APAH
  • CTD – APAH
  • CHD – APAH
  • Toxic – APAH
  • HIV – APAH
• Study Duration for individual patient: Up to 6 years
• Contact: https://clinicaltrials.gov/ct2/show/NCT02932410?term=TOMORROW&rank=1
• Listing on clinicaltrials.gov